346
In phase III clinical trials, the telithromycin 800 mg once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.
 patients with community-acquired pneumonia: Subject; telithromycin 800 mg once-daily dose: Treatment; S. pneumoniae: Treatment.Disorder; Haemophilus influenzae: Treatment.Disorder; Staphylococcus aureus: Treatment.Disorder; pneumonia: Treatment.Disorder; telithromycin: Treatment.Drug; 800 mg: Treatment.Dosage; once-daily: Treatment.Freq
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with community-acquired pneumonia: Subject; telithromycin 800 mg once-daily dose: Treatment; S. pneumoniae: Treatment.Disorder; Haemophilus influenzae: Treatment.Disorder; Staphylococcus aureus: Treatment.Disorder; pneumonia: Treatment.Disorder; telithromycin: Treatment.Drug; 800 mg: Treatment.Dosage; once-daily: Treatment.Freq